Hematopoietic growth factors—use in normal blood and stem cell donors: clinical and ethical issues

475. 99. Bussel JB, Kuter DJ, George LN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-81. 100. Kuter D, Bussel J, George J, Aledort L, Lichtin A, Lyons R, Nieva J, Wasser J, Bourgeois E, Kappers-Klunne M, Lefrere F, Schipperus M, Kelly R, Christal J, Guo M, Nichol J. Longterm dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update [abstract]. Blood 2006;108:144a, abstract #476. 101. McHutchison JG, Dusheiko G, Shiffman ML, RodriguezTorres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH; TPL102357 Study Group. Eltrombopag for thrombocytopenic in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-36. 102. Spivak JL. Recombinant human erythropoietin and its role in transfusion medicine. Transfusion 1994;34:1-4. 103. Fullerton DA, Campbell DN, Whitman GJ. Use of human recombinant erythropoietin to correct severe preoperative anemia. Ann Thorac Surg 1991;51:825-6. 104. Gaudiani VA, Mason HD. Preoperative erythropoietin in Jehovah’s Witnesses who require cardiac procedures. Ann Thorac Surg 1991;41:823-4. 105. Shi PA, Ness PM. Two-unit red cell apheresis and its potential advantages over traditional whole blood donation: a review. Transfusion 1999;39:218-25. 106. Bahlmann FH, Groot K, Spandau J-M, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:921-6. 107. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994;

[1]  T. Berg,et al.  Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. , 2007, The New England journal of medicine.

[2]  J. George,et al.  Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura , 2007 .

[3]  Wilson Roa,et al.  Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. L. Wallace,et al.  Blood collection and transfusion in the United States in 2001 , 2007, Transfusion.

[5]  P. Bierman,et al.  Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project , 2006, British journal of haematology.

[6]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[7]  H. Miyazaki,et al.  Domain Subclass Conversion Improved Activity of Anti-Mpl Agonist Antibodies in the Form of Whole IgG. , 2006 .

[8]  R. Desjardins,et al.  Single and Multiple Oral Doses of AKR-501 (YM477) Increase the Platelet Count in Healthy Volunteers. , 2006 .

[9]  J. Bussel,et al.  Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor. , 2006 .

[10]  J. Bussel,et al.  Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura : 2-year update , 2006 .

[11]  S. Mackinnon,et al.  The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors , 2006, Bone Marrow Transplantation.

[12]  J. George,et al.  AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. , 2006, The New England journal of medicine.

[13]  S. Schoenberg,et al.  Autologous Bone Marrow Stem Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor After Subacute ST-Segment Elevation Myocardial Infarction Undergoing Late Revascularization : Final Results From the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infar , 2006 .

[14]  D. Link,et al.  Cytokines and hematopoietic stem cell mobilization , 2006, Journal of cellular biochemistry.

[15]  D. Cogdell,et al.  Recombinant human granulocyte–colony‐stimulating factor–mobilized and apheresis‐collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis , 2006, Transfusion.

[16]  S. Kajigaya,et al.  Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor , 2006, Proceedings of the National Academy of Sciences.

[17]  A. M. Leone,et al.  Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. , 2006, International journal of cardiology.

[18]  C. Buchta,et al.  The above letter was sent to Buchta et al.; Drs Buchta and Dettke offered the following reply , 2006 .

[19]  C. Dunbar,et al.  AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. , 2006, Blood.

[20]  H. Johnsen,et al.  Stem Cell Mobilization Induced by Subcutaneous Granulocyte-Colony Stimulating Factor to Improve Cardiac Regeneration After Acute ST-Elevation Myocardial Infarction: Result of the Double-Blind, Randomized, Placebo-Controlled Stem Cells in Myocardial Infarction (STEMMI) Trial , 2006, Circulation.

[21]  J. Mehta,et al.  Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure. , 2006, The American journal of cardiology.

[22]  M. Schwaiger,et al.  Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. , 2006, JAMA.

[23]  K. Matsuo,et al.  Transient respiratory disturbance by granulocyte–colony‐stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation , 2006, Transfusion.

[24]  R. Storb,et al.  Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. , 2005, Blood.

[25]  H. Koblish,et al.  Stimulation of Platelet Production in Healthy Volunteers by a Novel Pegylated Peptide-Based Thrombopoietin (TPO) Receptor Agonist. , 2005 .

[26]  B. Klein,et al.  The risk of posterior subcapsular cataracts in granulocyte donors , 2005, Transfusion.

[27]  D. Link,et al.  G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. , 2005, Blood.

[28]  A. Arai,et al.  Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. , 2005, Journal of the American College of Cardiology.

[29]  J. Baselga,et al.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Dipersio,et al.  The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. , 2005, Blood.

[31]  C. Nienaber,et al.  Prevention of Left Ventricular Remodeling With Granulocyte Colony-Stimulating Factor After Acute Myocardial Infarction: Final 1-year Results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE- , 2005, Circulation.

[32]  S. Masuda,et al.  Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. , 2005, The New England journal of medicine.

[33]  B. Wood,et al.  Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist , 2005, Transfusion.

[34]  M. Tsuchiya,et al.  A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. , 2005, Blood.

[35]  J. T. Sullivan,et al.  Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand , 2004, Clinical pharmacology and therapeutics.

[36]  M. Tendera,et al.  Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ Stem Cells, and Mononuclear Cells Expressing Early Cardiac, Muscle, and Endothelial Markers Into Peripheral Blood in Patients With Acute Myocardial Infarction , 2004, Circulation.

[37]  C. Erickson-Miller,et al.  An Oral, Non-Petide, Small Molecule Thrombopoietin Receptor Agonist Increases Platelet Counts in Healthy Subjects. , 2004 .

[38]  D. Margolis,et al.  Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. , 2004, Journal of pediatric hematology/oncology.

[39]  B. Newman.  Blood donor complications after whole-blood donation. , 2004, Current opinion in hematology.

[40]  D. Stroncek,et al.  Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF , 2004, Journal of Translational Medicine.

[41]  P. Appelbaum,et al.  Therapeutic misconception in clinical research: frequency and risk factors. , 2004, IRB.

[42]  M. Hino,et al.  Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest , 2004, Bone Marrow Transplantation.

[43]  D. Fliser,et al.  Erythropoietin regulates endothelial progenitor cells. , 2004, Blood.

[44]  K. Matsuo,et al.  Elevation of serum hepatocyte growth factor during granulocyte colony‐stimulating factor‐induced peripheral blood stem cell mobilization , 2004, British journal of haematology.

[45]  C. Rübe,et al.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial , 2003, The Lancet.

[46]  B. Wood,et al.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. , 2003, Blood.

[47]  E. Crivellato,et al.  Erythropoietin as an angiogenic factor , 2003, European journal of clinical investigation.

[48]  C. Buchta,et al.  Donor exposure to the plasticizer di(2‐ethylhexyl)phthalate during plateletpheresis , 2003, Transfusion.

[49]  Bernd Hertenstein,et al.  G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. , 2003, Blood.

[50]  L. Trakhtenbrot,et al.  Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF , 2003, Bone Marrow Transplantation.

[51]  D. Follmann,et al.  G‐CSF‐induced spleen size changes in peripheral blood progenitor cell donors , 2003, Transfusion.

[52]  J. Bryant,et al.  Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  P. Anderlini,et al.  Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development , 2002, Bone Marrow Transplantation.

[54]  P. Marson,et al.  Legislative and ethical aspects of administering granulocyte colony-stimulating factor to normal donors. , 2002, Haematologica.

[55]  R. Hanada,et al.  Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. , 2002, Blood.

[56]  Y. Ikeda,et al.  Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. , 2002, Blood.

[57]  N. Russell,et al.  Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. , 2002, Experimental hematology.

[58]  R. Beal.  The International Society of Blood Transfusion and A Code of Ethics for Blood Donation and Transfusion (2000). , 2002, Vox sanguinis.

[59]  J. Tisdale,et al.  Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. , 2002, Blood.

[60]  C. Yang,et al.  Thrombocytopenia caused by the development of antibodies to thrombopoietin. , 2001, Blood.

[61]  R. Strauss,et al.  Cataracts in neutrophil donors stimulated with adrenal corticosteroids , 2001, Transfusion.

[62]  W. Mayr,et al.  Kinetics of CFU‐Mk after automated plateletpheresis , 2001, Vox sanguinis.

[63]  D. Devine,et al.  Generation of reticulated platelets in responseto whole blood donation or plateletpheresis , 2001, Transfusion.

[64]  J. Dipersio,et al.  Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. , 2001, Blood.

[65]  S. Leitman,et al.  Comprehensive analysis of citrate effects during plateletpheresis in normal donors , 2001, Transfusion.

[66]  J. Dipersio,et al.  Thrombopoietin therapy increases platelet yields in healthy platelet donors. , 2001, Blood.

[67]  D. Stroncek,et al.  Administration of G–CSF plus dexamethasone producesgreater granulocyte concentrate yields while causing nomore donor toxicity than G–CSF alone , 2001, Transfusion.

[68]  A. Grigg,et al.  Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. , 2001, Blood.

[69]  T. Murohara,et al.  Mobilization of Endothelial Progenitor Cells in Patients With Acute Myocardial Infarction , 2001, Circulation.

[70]  S. Leitman,et al.  Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations , 2001, Transfusion.

[71]  J. Prchal,et al.  Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. , 2001, Blood.

[72]  G. Ehninger,et al.  Spleen enlargement in healthy donors during G–CSF mobilization of PBPCs , 2001, Transfusion.

[73]  M. Gertz,et al.  Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. , 2000, Journal of hematotherapy & stem cell research.

[74]  A J Matas,et al.  Nondirected donation of kidneys from living donors. , 2000, The New England journal of medicine.

[75]  D. Link,et al.  Expression of the G-CSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF. , 2000, Blood.

[76]  C. Verschraegen,et al.  Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic Cancer , 2000, Annals of Internal Medicine.

[77]  T. Ulich,et al.  A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. , 1999, Experimental hematology.

[78]  D. Stroncek,et al.  Effects of granulocyte–colony‐stimulating factor on potential normal granulocyte donors , 1999, Transfusion.

[79]  R. Zimmermann,et al.  The influence of automated plateletpheresis on systemic levels of hematopoietic growth factors , 1999, Transfusion.

[80]  R. Domen,et al.  An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. , 1999, Archives of pathology & laboratory medicine.

[81]  S. Vuk-Pavlović,et al.  Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. , 1999, Blood.

[82]  M Marchetti,et al.  Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. , 1999, Blood.

[83]  F. Aversa,et al.  Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor , 1999, The Lancet.

[84]  P. Ness,et al.  Two‐unit red cell apheresis and its potential advantages over traditional whole‐blood donation , 1999, Transfusion.

[85]  L. Moldawer,et al.  Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. , 1999, Blood.

[86]  D. Kuter.  The use of PEG‐rHuMGDF in platelet apheresis , 1998, Stem cells.

[87]  M. Dettke,et al.  Measurement of the levels of reticulated platelets after plateletpheresis to monitor activity of thrombopoiesis , 1998, Transfusion.

[88]  M. Dettke,et al.  Increase in endogenous thrombopoietin in healthy donors after automated plateletpheresis , 1998, Transfusion.

[89]  J. Laver,et al.  Granulocytosis causing sickle-cell crisis , 1998, The Lancet.

[90]  Brown Sl,et al.  Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[91]  Ulla-Britt Jönsson,et al.  Effects of in vivo administration of G‐CSF on neutrophil and eosinophil adhesion , 1997, British journal of haematology.

[92]  M. Dew,et al.  Understanding donors' motivations: a study of unrelated bone marrow donors. , 1997, Social science & medicine.

[93]  R. Champlin,et al.  Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim , 1997, Transfusion.

[94]  M. Freedman.  Safety of long‐term administration of granulocyte colony‐stimulating factor for severe chronic neutropenia , 1997, Current opinion in hematology.

[95]  W. Piacibello,et al.  Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. , 1997, Blood.

[96]  G. Pihan,et al.  Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[97]  R. Figlin,et al.  Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. , 1997, The New England journal of medicine.

[98]  P. Venge,et al.  Administration of G‐CSF to healthy subjects: the effects on eosinophil counts and mobilization of eosinophil granule proteins , 1997, British journal of haematology.

[99]  W. Liles,et al.  A comparative trial of granulocyte‐colony‐stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers , 1997, Transfusion.

[100]  D. Stroncek,et al.  Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells , 1996, Transfusion.

[101]  G. Chatta,et al.  Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. , 1996, Blood.

[102]  M. Harada,et al.  Effects of granulocyte colony-stimulating factor on the hemostatic system in healthy volunteers. , 1996, International journal of hematology.

[103]  D. Hasenclever,et al.  Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. , 1996, Bone marrow transplantation.

[104]  F. Holsboer,et al.  Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. , 1996, Blood.

[105]  A. Roberts,et al.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.

[106]  M. Andreeff,et al.  Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. , 1995, Blood.

[107]  R. Jacobs,et al.  Combined transplantation of allogeneic bone marrow and CD34+ blood cells. , 1995, Blood.

[108]  M. Hirokawa,et al.  Granulocyte colony-stimulating factor downregulates allogeneic immune responses by posttranscriptional inhibition of tumor necrosis factor-alpha production. , 1995, Blood.

[109]  T. Hartung,et al.  Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. , 1995, Blood.

[110]  A. Ohsaka,et al.  Granulocyte colony‐stimulating factor administration modulates the surface expression of effector cell molecules on human monocytes , 1995, British journal of haematology.

[111]  C. Hack,et al.  Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. , 1994, Blood.

[112]  R. Allen,et al.  Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. , 1994, Blood.

[113]  E. Thorsby,et al.  CHARACTERIZATION OF CD34+ PERIPHERAL BLOOD CELLS FROM HEALTHY ADULTS MOBILIZED BY RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR , 1994 .

[114]  A. Anagnostou,et al.  Erythropoietin receptor mRNA expression in human endothelial cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[115]  J. Spivak.  Recombinant human erythropoietin and its role in transfusion medicine , 1994, Transfusion.

[116]  S. Kondo,et al.  Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. , 1993, The Journal of clinical investigation.

[117]  Y. Niitsu,et al.  Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. , 1993, Bone marrow transplantation.

[118]  V. Gaudiani,et al.  Preoperative erythropoietin in Jehovah's Witnesses who require cardiac procedures. , 1991, The Annals of thoracic surgery.

[119]  D. Fullerton,et al.  Use of human rocombinant erythropoietin to correct severe preoperative anemia. , 1991, The Annals of thoracic surgery.

[120]  T J Walsh,et al.  Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. , 1991, The Journal of infectious diseases.

[121]  J. Adamson,et al.  Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. , 1989, Annals of internal medicine.

[122]  M. Kaliner,et al.  Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas. , 1986, The New England journal of medicine.

[123]  R. Kahn,et al.  Donor Platelet Response and Product Quality Assurance in Plateletpheresis , 1981, Transfusion.

[124]  J. Clarke,et al.  Medicine , 1907, Bristol medico-chirurgical journal.

[125]  Y. Kilic,et al.  Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. , 2006, Haematologica.

[126]  J. Stypmann,et al.  Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure--Feasibility, safety and effects on exercise tolerance and cardiac function. , 2006, Basic research in cardiology.

[127]  S. Miller,et al.  Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. , 2005, Experimental hematology.

[128]  D. Blaise,et al.  rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells , 2005, Bone Marrow Transplantation.

[129]  N. Arima,et al.  Acute lung Injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. , 2005, Haematologica.

[130]  A. Nagler,et al.  Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. , 2004, Experimental hematology.

[131]  Avid,et al.  THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .

[132]  R. Moore,et al.  Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. , 1998, Blood.

[133]  R. Strauss.  Effects on donors of repeated leukocyte losses during plateletpheresis , 1994, Journal of clinical apheresis.

[134]  E. Thorsby,et al.  Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. , 1994, Blood.

[135]  D. Fullerton,et al.  Use of human recombinant erythropoietin to correct severe preoperative anemia. , 1991, The Annals of thoracic surgery.